JSJeffrey James Swigris

Jeffrey James Swigris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey James Swigris has a total of 362 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Using Bookmarking to Reveal Dyspnea Severity Categorizations According to Patients with Interstitial Lung Disease and the Physicians Who Treat Them

    by Jeffrey J. Swigris, Joseph B. Pryor, Kerri I. Aronson, Taylor A. Guess, Joshua J. Solomon

    Rationale: Dyspnea impairs the quality of life of patients with interstitial lung disease (ILD). To deliver the best care to patients with ILD, practitioners must understand how patients view and categorize dyspnea severity. Item response theory (IRT) analyses use a probabilistic model to explain the association between an abstract construct (here, dyspnea severity) and observed data (e.g., responses to a dyspnea questionnaire). Bookmarking is a method for establishing cut-points along the range of a questionnaire’s score to define severity categories. Objectives: We performed an IRT analysis on response data from the University of California San Diego Shortness of Breath questionnaire administered at the time of enrollment into the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR). Results of the IRT were used to generate a book of hypothetical patient vignettes, which were ordered from no dyspnea (first page) to most severe dyspnea (last page). Convenience samples of patients with ILD and ILD physicians were recruited to work in groups to decide where bookmarks should be placed to divide the vignette book into categories of overall dyspnea severity. Results: Data from 1,760 patients in the PFF-PR were used in the IRT analysis. Twenty-one vignettes were generated to cover the full spectrum of dyspnea severity. There appeared to be no differences in bookmark positions between female and male ILD physicians or between patient groups based on supplemental oxygen use. Patients and physicians bookmarked dyspnea similarly at the mild end of the dyspnea severity spectrum, but at the severe end, patients rated dyspnea more severely than physicians. When applied back to the registrants in the PFF-PR, patients’ bookmarks categorized 177 (10%) registrants with more severe dyspnea than physicians’ bookmarks, including 159 (9%) registrants who would be classified with “severe” dyspnea according to patients but only “moderate” dyspnea according to the physicians. Conclusions: Patients and ILD physicians categorize dyspnea similarly at the milder end of the severity spectrum, but patients view dyspnea more severely than physicians at the higher end. Remaining aware of this in clinical encounters could improve understanding of patients’ experiences living with ILD and enhance empathy in the patient–physician relationship.


  • Interstitial Lung Disease Patients’ Global Impressions of Symptoms, Severity Ratings, and Meaningfulness of Changes Over Time

    by Jeffrey J. Swigris, Joseph B. Pryor, Kerri I. Aronson, Taylor A. Guess, Joshua J. Solomon

    In interstitial lung disease (ILD), symptoms drive impairments in health-related quality of life (HRQL). Patient-reported outcome measures (PROs) can assess whether interventions change symptom severity. The meaningfulness of change in a PRO's score is estimated by anchoring it to a related variable for which meaningful change has been previously established. Patient global impressions of severity (PGIS) are single item PROs that may make trustworthy anchors, but for ILD, the meaningfulness of change in PGIS items for shortness of breath, cough, and fatigue/low energy are unknown. To improve understanding of how patients with ILD rate and categorize symptoms; how differing levels of symptom severity affect lived experiences; and how patients derive and apply meaningfulness to change in symptoms. We used one-on-one interviews and an electronic survey to collect data from patients with various forms of ILD. Interviews were conducted to provide richness and context to survey responses. We conducted certain analyses with respondents stratified by oxygen use. Interviewees (N=18) confirmed shortness of breath (SOB), cough and fatigue/low energy are the most bothersome symptoms of ILD. Among 298 survey respondents, on a PGIS for SOB with a 0 to 4 numeric rating scale, on average, those who used O2 had more severe SOB than non-users, and most respondents considered a 2-point change meaningful for worsening (45.5%) or improvement (47.2%). On a PGIS with a 5-option ordinal response scale, for SOB, most considered a 1-category change meaningful for worsening (49.8%) and a 2-category change meaningful for improvement (42.3); for cough frequency, most respondents considered a 1-category change on the 5-option ordinal response scale meaningful for worsening (48.2%) or improvement (45.0%). Survey responses for how SOB is now compared to 3 months ago (patient global impressions of change or PGIC) were biased toward the present state. PGIS's can be used as anchors for meaningful change analyses of PRO's that assess SOB or cough in patients with ILD. PGIC's demonstrate present state bias and should not be used. Patients' descriptions paint a vivid picture of lived experience with varying levels of symptom severity and can help contextualize change scores.


  • Top Cited Papers

    Deep Learning Classification of Usual Interstitial Pneumonia Predicts Outcomes

    by Stephen M. Humphries, Devlin Thieke, David Baraghoshi, Matthew J. Strand, Jeffrey J. Swigris, Kum Ju Chae, Hye Jeon Hwang, Andrea S. Oh, Kevin R. Flaherty, Ayodeji Adegunsoye, et al.

    Rationale: Computed tomography (CT) enables noninvasive diagnosis of usual interstitial pneumonia (UIP), but enhanced image analyses are needed to overcome the limitations of visual assessment. Objectives: Apply multiple instance learning (MIL) to develop an explainable deep learning algorithm for prediction of UIP from CT and validate its performance in independent cohorts. Methods: We trained an MIL algorithm using a pooled dataset (n = 2,143) and tested it in three independent populations: data from a prior publication (n = 127), a single-institution clinical cohort (n = 239), and a national registry of patients with pulmonary fibrosis (n = 979). We tested UIP classification performance using receiver operating characteristic analysis, with histologic UIP as ground truth. Cox proportional hazards and linear mixed-effects models were used to examine associations between MIL predictions and survival or longitudinal FVC. Measurements and Main Results: In two cohorts with biopsy data, MIL improved accuracy for histologic UIP (area under the curve, 0.77 [n = 127] and 0.79 [n = 239]) compared with visual assessment (area under the curve, 0.65 and 0.71). In cohorts with survival data, MIL-UIP classifications were significant for mortality (n = 239, mortality to April 2021: unadjusted hazard ratio, 3.1; 95% confidence interval [CI], 1.96–4.91; P < 0.001; and n = 979, mortality to July 2022: unadjusted hazard ratio, 3.64; 95% CI, 2.66–4.97; P < 0.001). Individuals classified as UIP positive by the algorithm had a significantly greater annual decline in FVC than those classified as UIP negative (−88 ml/yr vs. −45 ml/yr; n = 979; P < 0.01), adjusting for extent of lung fibrosis. Conclusions: Computerized assessment using MIL identifies clinically significant features of UIP on CT. Such a method could improve confidence in radiologic assessment of patients with interstitial lung disease, potentially enabling earlier and more precise diagnosis.


  • Open Access

    A first look at the reliability, validity and responsiveness of L-PF-35 dyspnea domain scores in fibrotic hypersensitivity pneumonitis

    by Jeffrey J. Swigris, Kerri Aronson, Evans R. Fernández Pérez

    Background: Dyspnea impairs quality of life (QOL) in patients with fibrotic hypersensitivity pneumonitis (FHP). The Living with Pulmonary Fibrosis questionnaire (L-PF) assesses symptoms, their impacts and PF-related QOL in patients with any form of PF. Its scores have not undergone validation analyses in an FHP cohort. Methods: We used data from the Pirfenidone in FHP trial to examine reliability, validity and responsiveness of the L-PF-35 Dyspnea domain score (Dyspnea) and to estimate its meaningful within-patient change (MWPC) threshold for worsening. Lack of suitable anchors precluded conducting analyses for other L-PF-35 scores. Results: At baseline, Dyspnea’s internal consistency (Cronbach’s coefficient alpha) was 0.85; there were significant correlations with all four anchors (University of California San Diego Shortness of Breath Questionnaire scores r = 0.81, St. George’s Activity domain score r = 0.82, percent predicted forced vital capacity r = 0.37, and percent predicted diffusing capacity of the lung for carbon monoxide r = 0.37). Dyspnea was significantly different between anchor subgroups (e.g., lowest percent predicted forced vital capacity (FVC%) vs. highest, 33.5 ± 18.5 vs. 11.1 ± 9.8, p = 0.01). There were significant correlations between changes in Dyspnea and changes in anchor scores at all trial time points. Longitudinal models further confirmed responsiveness. The MWPC threshold estimate for worsening was 6.6 points (range 5–8). Conclusion: The L-PF-35 Dyspnea domain appears to possess acceptable psychometric properties for assessing dyspnea in patients with FHP. Because instrument validation is never accomplished with one study, additional research is needed to build on the foundation these analyses provide. Trial registration: The data for the analyses presented in this manuscript were generated in a trial registered on ClinicalTrials.gov; the identifier was NCT02958917.


  • Open Access

    Reliability and responsiveness of the D12 and validity of its scores as a measure of dyspnoea severity in patients with rheumatoid arthritis-related interstitial lung disease

    by Jeffrey J Swigris, Sonye Danoff, Paul F Dellaripa, Tracy J Doyle, Joshua J Solomon

    Background Interstitial lung disease due to rheumatoid arthritis (RA-ILD) affects a substantial minority of patients with RA, inducing life-altering symptoms, impairing quality of life (QOL) and forcing patients to confront the potential for shortened survival. Dyspnoea is the predominant respiratory symptom of RA-ILD and a strong driver of QOL impairment in patients with it. The D12 is a 12-item questionnaire that assesses the physical and affective components of dyspnoea. It was one of a battery of patient-reported outcomes used in the double-blind, placebo-controlled TRAIL 1 trial of pirfenidone for RA-ILD. There is little information on the reliability, validity or responsiveness of the D12 in RA-ILD. Methods In accordance with COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) methodology, we conducted analyses on data from the TRAIL 1 trial to assess the measurement properties of the D12. Results Internal consistency (α=0.95, 0.95, 0.95, 0.95 and 0.96 at baseline, 13, 26, 39 and 52 weeks) and test-retest reliability 0.85 (0.71 to 0.92) exceeded acceptability criteria. Well over the 75% benchmark of hypotheses (43/46=93%) around D12 measurement properties were confirmed. Known-groups validity was supported by significant differences between subgroups of patients with differing levels of dyspnoea (eg, St. George’s Respiratory Questionnaire (SGRQ) Activity score ≥50 vs Conclusions D12 scores possess acceptable measurement properties in RA-ILD, such that it can be used with confidence in this population to assess dyspnoea severity defined by its physical and affective components. As validation is an ongoing process, and never accomplished in a single study, additional research on the psychometric properties of the D12 in RA-ILD is encouraged.


  • Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort

    by Kerri I. Aronson, Adam M. Martin-Schwarze, Jeffrey J. Swigris, Giselle Kolenic, Jamuna K. Krishnan, Anna J. Podolanczuk, Robert J. Kaner, Fernando J. Martinez, Monika M. Safford, Laura C. Pinheiro

    Rationale: Fatigue is a common and debilitating symptom for people living with interstitial lung disease (ILD). Studies on fatigue in ILD are limited, and little headway has been made toward developing interventions targeting the alleviation of fatigue. A barrier to progress is a lack of knowledge around the performance characteristics of a patient-reported outcome measure to assess fatigue in patients with ILD. Objectives: To assess the validity and reliability of the Fatigue Severity Scale (FSS) for measuring fatigue in a national cohort of patients with ILD. Methods: FSS scores and several anchors were measured in 1,881 patients from the Pulmonary Fibrosis Foundation Patient Registry. Anchors included the Short Form 6D Health Utility Index (SF-6D) score and a single vitality question from the SF-6D; the University of California, San Diego, Shortness of Breath Questionnaire; FVC; Dl CO; and 6-minute-walk distance. Internal consistency reliability, concurrent validity, and known-groups validity were assessed. Structural validity was assessed using confirmatory factor analysis. Measurements and Main Results: The FSS demonstrated high internal consistency (Cronbach’s α = 0.96). There were moderate to strong correlations between FSS score and patient-reported anchors (vitality question from the SF-6D [r = 0.55] and University of California, San Diego, Shortness of Breath Questionnaire total score [r = 0.70]) and weak correlations between FSS score and physiological measures (FVC [r = −0.24], percentage predicted Dl CO [r = −0.23], and 6-minute-walk distance [r = −0.29]). Higher mean FSS scores, indicating greater fatigue, were observed among patients using supplemental oxygen, those prescribed steroids, and those with lower percentage predicted FVC and percentage predicted Dl CO. The confirmatory factor analysis results suggest that the nine questions of the FSS reflect one dimension of fatigue. Conclusions: Fatigue is an important patient-centered outcome in ILD that is poorly correlated with physiological measures of disease severity, including lung function and walk distance. These findings further support the need for a reliable and valid measure of patient-reported fatigue in ILD. The FSS possesses acceptable performance characteristics for assessing fatigue and distinguishing different degrees of fatigue among patients with ILD.


  • Open Access

    Is it time to include oxygen needs as an endpoint in clinical trials in patients with fibrosing interstitial lung disease? If so, how?

    by Kerri Aronson, Susan S Jacobs, Dawn Repola, Jeffrey J Swigris

    Many patients with fibrosing interstitial lung disease (fILD) will need to use supplemental oxygen (O2) to maintain normoxia at some point in their illness. If it is not needed at the time of diagnosis, then if fILD progresses—or if a comorbid condition like pulmonary hypertension develops—O2 will become necessary, often, initially, during exertion and all-too-often, eventually, at rest as well. But presumably, if all else remains stable, if fILD progression is halted or slowed, O2 needs follow in parallel. Despite perceived or unnoticed benefits of O2, and prescribers’ good intentions to improve patients’ sense of well-being, patients with fILD generally view O2 with frustration and fear, as it threatens their already-impaired quality of life. Because of how meaningful and impactful O2 is to the lives of patients with fILD, ‘O2 need’ is a critically important—and perhaps the most—patient-centred metric that should be considered for incorporation as an endpoint in therapeutic trials. It is unclear how this should be done, but in this paper, we offer some possible approaches that merit consideration.


  • Quantitative High-Resolution Computed Tomography Predicts Progressive Pulmonary Fibrosis

    by M. Koslow, D. Baraghoshi, M. Strand, J. Solomon, J.J. Swigris, D.A. Lynch, M.P. Mohning, Z.X. Yunt, R. Keith, E. Fernandez Perez, et al.